Celik, E. Et Al. 2021. Classical versus non-classical EGFR mutations: Erlotinib response and impact of renal insufficiency. Journal of Oncology Pharmacy Practice , vol.27, no.7 , 1665-1673.

Celik, E., Samanci, N. S., KARADAĞ, M., DEMİRCİ, N. S., Cikman, D. I., Derin, S., ... Bedir, S.(2021). Classical versus non-classical EGFR mutations: Erlotinib response and impact of renal insufficiency. Journal of Oncology Pharmacy Practice , vol.27, no.7, 1665-1673.

Celik, Emir Et Al. "Classical versus non-classical EGFR mutations: Erlotinib response and impact of renal insufficiency," Journal of Oncology Pharmacy Practice , vol.27, no.7, 1665-1673, 2021

Celik, Emir Et Al. "Classical versus non-classical EGFR mutations: Erlotinib response and impact of renal insufficiency." Journal of Oncology Pharmacy Practice , vol.27, no.7, pp.1665-1673, 2021

Celik, E. Et Al. (2021) . "Classical versus non-classical EGFR mutations: Erlotinib response and impact of renal insufficiency." Journal of Oncology Pharmacy Practice , vol.27, no.7, pp.1665-1673.

@article{article, author={Emir Celik Et Al. }, title={Classical versus non-classical EGFR mutations: Erlotinib response and impact of renal insufficiency}, journal={Journal of Oncology Pharmacy Practice}, year=2021, pages={1665-1673} }